ProShares UltraShort NASDAQ Biotechnology
16 hedge funds and large institutions have $15.6M invested in ProShares UltraShort NASDAQ Biotechnology in 2014 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 2 closing their positions.
356% more call options, than puts
Call options by funds: $2.23M | Put options by funds: $488K
350% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 2
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
78% more funds holding
Funds holding: 9 → 16 (+7)
23% more capital invested
Capital invested by funds: $12.7M → $15.6M (+$2.86M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FAM
Fred Alger Management
New York
|
+$1.89M |
| 2 |
FTUS
Flow Traders U.S.
New York
|
+$1.15M |
| 3 |
Jane Street
New York
|
+$856K |
| 4 |
BMO
Beck Mack & Oliver
New York
|
+$665K |
| 5 |
HighTower Advisors
Chicago,
Illinois
|
+$625K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Zurich Cantonal Bank
Zurich,
Switzerland
|
-$1.14M |
| 2 |
ST
Spot Trading
Chicago,
Illinois
|
-$325K |
| 3 |
U
UBS
Zurich,
Switzerland
|
-$9.05K |
BIS Hedge Fund Activity: Q3 2014 in Review
16 of the 3,448 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraShort NASDAQ Biotechnology (BIS) for Q3 2014, worth a combined $15.6M — up 23% from $12.7M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new BIS positions and 2 closed out — a net gain of 7 holders — while 4 added to existing stakes and 1 trimmed.
The largest buyer was Fred Alger Management, opening a new position worth an estimated $1.89M. The largest seller was Zurich Cantonal Bank, exiting entirely with an estimated $1.14M sold.
- 16 institutional investors held ProShares UltraShort NASDAQ Biotechnology (BIS) as of Q3 2014, up from 9 in Q2 2014.
- Funds reported $15.6M of ProShares UltraShort NASDAQ Biotechnology stock for Q3 2014, up 23% quarter-over-quarter.
- 9 funds opened new ProShares UltraShort NASDAQ Biotechnology positions in Q3 2014 and 2 closed out, a net change of +7 holders.
- The largest ProShares UltraShort NASDAQ Biotechnology buyer in Q3 2014 was Fred Alger Management, an estimated $1.89M added.
- The largest ProShares UltraShort NASDAQ Biotechnology seller in Q3 2014 was Zurich Cantonal Bank, an estimated $1.14M sold.
Based on aggregated 13F filings for Q3 2014.